ABOUT HEPAR-P™
Name of the product
HEPAR-P™
250 mg capsule
The packing of HEPAR-P™
60 capsules
per bottle
Goals of therapy
Hispatological
of liver HBeAg Seroconversion,
[loss of HBeAg (Hepatitis Be Antigen) and appearance of
anti-HBeAg] Decreasing
of the level of liver enzymes (ALT, AST) Reduction
of HBV DNA to undetectable level, [to stop progression of
liver injury by eradicating viral replication or eliminating
infection]
Chemical definition
HEPAR-P™ capsule contains
250 mg standardised Phyllanthus niruri extract EPN 797.
The
product is standardised to contain:
The proven efficacy of pharmaceutical preparations
with Phyllanthus niruri is established with the above specifications.
These are achievable only through the strict isolation and subsequent
blending of the individual activities. Evidence suggests that tannins,
e.g. corilagin is the most therapeutically active component since
it has been long known to effectively bind certain animal and plant
virus particles.
Standardised Phyllanthus niruri extract EPN 797
complies with pharmaceutical standards of low residual solvents,
microbiology and levels of impurities.
Dosage of administration
HEPAR-P™
is 2 capsules to be taken orally, 3
times a day .
Duration
of treatment:
In HBsAg positive patients treatment
should be administrated at least 6 months.(If HEPAR-P™ capsule
is discontinued, patients should be periodically
monitored for evidence of recurrent hepatitis).
In individuals with abnormality in liver
functions , 1 to 2 capsules three times
a day.
In individuals for liver protection
from alcohol intake, 2 capsules right before or
after drinking.
In individuals for general health maintenance ,
1 capsules, twice a day.
Contra-indications
HEPAR-P™ has shown no contra-indication.
Pregnancy and lactation
No study has shown evidence of side effect. However, the
safety of herbal products in human pregnancy has not
been
established and animal studies are not always predictive
of the human response. Therefore, administration of
HEPAR-P™ is not recommended during the pregnancy.
Lactation: ™
do not breast feed their infants, or not to take HEPAR-P™
if you wish to breastfeeding your infants.
Toxicity
Our
lab study has shown no toxic effects in acute and sub-acute
oral administration up to 5g/kg/day in rat for 2 weeks
and 3 months. No organ toxicity, no fatalities occurred,
no specific signs or symptoms have been identified following
such overdose.
Refer
to our toxicology studies >>
Storage Conditions
Store the product at temperature between 15ºC and 30ºC. Keep away from children.
